Neurofarmacologia i dolor

grup d

El grup centra la seva recerca en la comprensió de la funció dels receptors de neurotransmissors en salut i malaltia. Per tant, el seu principal objectiu és traduir els resultats del laboratori al pacient i la pràctica clínica. En conseqüència, busquen noves estratègies farmacològiques per assolir una gestió eficaç de malalties neurològiques, neuropsiquiàtriques, inflamatòries, autoimmunes i del dolor.

 

  • Línies Estratègiques
  1. Implementació de la Fotofarmacologia  en el tractament de malalties del sistema nerviós central, inflamatòries i autoimmunes.
  2. Oligomerització de receptors acoblats a proteïna G, canals iònics i proteïnes interaccionants en el marc de les malalties neuropsiquiàtriques i dolor.
  3. Estudi de la funcionalitat de les interaccions oligomèriques en models animals per establir les bases del tractament farmacològic combinat.
  4. Avaluació clínica dels medicaments en les malalties neuropsiquiàtriques i dolor amb mètodes

  • Developing sigma-1 receptor screening assays and sigma-2 protein-protein interaction discovery.
    Company/entity: Laboratorios del Dr. Esteve, S.A
    Principal investigator: Francisco Ciruela Alférez
    Amount: 35.000 €
    Duration: 14/12/2018-30/12/2019

 

  • El complejo trans-sináptico formado por CB1-A2A y mGluY en el hipocampo como sustrato de los efectos terapéuticos de los cannabinoides en la enfermedad de Alzheimer (TRANSCANAD)
    Entitat finançadora: Ministerio de Ciencia Innovación y Universidades
    Referència: RTI2018-097773-A-I00
    Investigador principal: Ester Aso Pérez
    Import concedit: 145.000 euros  
    Durada: 2019-2021

  • Docents

M. L. Cuffí1 J.-E. Vilaseca2, M. Á. García2 (2019). Experience of collaborative work between students of health sciences and media communication. The GUNi 7th HIGHER EDUCATION IN THE WORLD REPORT (HEIW7): 'Humanities and Higher Education: generating synergies between Science, Technology and Humanities'.

 

  • Científiques

1.  Notartomaso, ​S., Scarselli, P., Di Pietro, P., Battaglia, G., Llebaria, A., Ciruela, F.x & Nicoletti, F. (2018). Mechanical allodynia assessment in a neuropathic pain murine model. Bio-protocol 8 (2): e2671.

 

2. Moreno, E., Chiarlone, A., Medrano, M., Puigdellívol, M., Bibic, L., Howell, L.A., Resel, E., Puente, N., Casarejos, M.J., Perucho, J., Suelves, N., Ciruela, F., Ginés, S., Galve-Roperh, I., Casadó, V., Grandes, P., Lutz, B., Monory, K., Canela E.I., Lluis, C., McCormick, P.J. & Guzmán, M. (2018). Singular location and signaling profile of adenosine A2A-cannabinoid CB1 receptor heteromers in the dorsal striatum. Neuropsychopharmacology 43 (5), 964-977.

 

3. Fernández-Dueñas, V., Ferré, S. & Ciruela, F.x (2018). Behavioral control by striatal A2A-dopamine D2 receptor heteromers. Neural Regeneration Research 13 (2), 241-243.

 

4. Ferré, S., Bonaventura, J, Zhu, W., Hatcher-Solis, C., Taura, J., Quiroz, C., Cai, N-S., Moreno, E., Casadó-Anguera, V., Kravitz, A.V., Thompson, K.R., Tomasi, D.G., Navarro. G., Cordomí, A., Pardo, L., Lluís, C., Dessauer, C.W., Volkow, N.D., Casadó, V., Ciruela, F., Logothetis, D.E. & Zwilling, D. (2018). Essential control of the function of the striatopallidal neuron by pre-coupled complexes of adenosine A2A-dopamine D2 receptor heterotetramers and adenylyl-cyclase. Frontiers in Pharmacology 9, 243.

 

5. Sahlholm, K.*x, Valle-León, M.*, Fernández-Dueñas, V. & Ciruela, F.x (2018). Pridopidine reverses phencyclidine-induced memory impairment. Frontiers in Pharmacology9, 338.

         *Equal contribution

 

6. Luján, R., Aguado, C., Ciruela, F., Cózar, J., Kleindienst, D., de la Ossa, L., Bettler, B., Wickman, K., Watanabe, M., Shigemoto, R. & Fukazawa, Y. (2018). Differential association of GABAB receptors with their effector ion channels in Purkinje cells. Brain Structure and Function 223(3),1565-1587.

 

7. Taura, J., Valle-León, M., Sahlholm, K., Watanabe, M., Van Craenenbroeck, K., Fernández-Dueñas, V., Ferré, S. & Ciruela, F.x (2018). Behavioral control by striatal adenosine A2A-dopamine D2 receptor heteromers. Genes, Brain & Behavior 17(4), e12432.

 

8. Sahlholm, K.*, Gómez-Soler, M.*, Valle-León, M., López-Cano, M., Taura, J., Watanabe, M., Ciruela, F.x & Fernández-Dueñas, V.x (2018). Antipsychotic efficacy of dopamine D2 receptor biased ligands is dependent on adenosine A2A receptor expression. Molecular Neurobiology 55 (6), 4952–4958.

*Equal contribution

 

9. Taura, J., Nolen E.G., Cabré, G., Hernando, J., Squarcialupi, L., López-Cano, M., Jacobson, K.A., Fernández-Dueñas, V. & Ciruela, F.x (2018). Remote control of movement disorders using a photoactivable adenosine A2A receptor antagonist. Journal of Controlled Release 283, 135-142.

 

10. Gómez de Salazar, M., Grau, C., Ciruela, F. & Altafaj, X. (2018). Phosphoproteomic alterations of ionotropic glutamate receptors in the hippocampus of the Ts65Dn mouse model of Down syndrome. Frontiers in Molecular Neuroscience 11, 226.

 

11.    Sahlholm, K.x, Valle-León, M., Taura, J., Fernández-Dueñas, V. & Ciruela, F.x (2018). Effects of the dopamine stabilizer, pridopidine, on basal and phencyclidine-induced hyperlocomotion: contribution of dopamine D2 and sigma-1 receptors.CNS & Neurological Disorders-Drug Targets 17 (7), 522 - 527.

 

12.    Wouters, E., Vasudevan, L., Ciruela, F., Saini, D.K., Stove, C. & Van Craenenbroeck, K. (2018). Assessing GPCR dimerization in living cells: comparison of the NanoBiT assay with related bioluminescence- and fluorescence-based approaches. Neuromethods 140, 239-250.

 

13.    Jung, C., Fernández-Dueñas, V., Plata, C., Garcia-Elias, A., Ciruela, F., Fernández-Fernández, J.M. & Valverde, M.A. (2018). Functional coupling of GABAA/B receptors and TRPV4 channel mediates rapid progesterone signaling in the oviduct. Science Signalling 11 (543), eaam6558.

 

14.    Gómez-Soler, M., Cordobilla, B., Morató, X., Fernández-Dueñas, V.x, Domingo, J.C.x & Ciruela, F.x (2018). Triglyceride form of docosahexaenoic acid mediates neuroprotection in experimental parkinsonism. Frontiers in Neuroscience 12, 604.

 

15.    Luján, R., Aguado, C., Ciruela, F., Morató, X., Watanabe, M., Adelman, J.P., Shigemoto, R. & Fukazawa, Y. (2017). SK2 channels associate with distinct Ca2+ sources in Purkinje cells. Frontiers in Cellular Neuroscience 12, 311.

 

16.    Morató, X., Luján, R., Gonçalves, N., Watanabe, M., Altafaj, X., Carvalho, A.L., Fernandez-Dueñas, V., Cunha, R.A. & Ciruela, F.x (2018). Metabotropic glutamate type 5 receptor requires contactin-associated protein 1 to control memory formation. Human Molecular Genetics 27 (20), 3528-3541.

 

17.    Núñez, F., Taura, J., Camacho, J., López-Cano, M., Fernández-Dueñas, V., Castro, N., Castro J.x & Ciruela, F.x (2018). PBF509, an adenosine A2A receptor antagonist, with efficacy in rodent models of movements disorders. Frontiers in Pharmacology, 9, 1200.

 

18.    Tasca, C.I., Lanznaster, D., Oliveira, K.A., Fernández-Dueñas, V. & Ciruela, F.(2018). Neuromodulatory effects of guanine-based purines in health and disease. Frontiers in Cellular Neuroscience 12, 376.

 

19.    Sahlholm, K., Valle-León, M., Fernández-Dueñas, V. & Ciruela, F.x (2018). Dopamine receptor heteromers: biasing antipsychotics. Future Medicinal Chemistry 10 (23).2675-2677

20. Esteve P, Rueda-Carrasco J, Inés Mateo M, Martin-Bermejo MJ, Draffin J, Pereyra G, Sandonís Á, Crespo I, Moreno I, Aso E, Garcia-Esparcia P, Gomez-Tortosa E, Rábano A, Fortea J, Alcolea D, Lleo A, Heneka MT, Valpuesta JM, Esteban JA, Ferrer I, Domínguez M, Bovolenta P. Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Nat Neurosci. 2019 Aug 22:1258-1268.

21. Aso E, Andrés-Benito P, Grau-Escolano J, Caltana L, Brusco A, Sanz P, Ferrer I. Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model. Cannabis Cannabinoid Res. Jun 2019

22. Aso E, Martinsson I, Appelhans D, Effenberg C, Benseny-Cases N, Cladera J, Gouras G, Ferrer I, Klementieva O. Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine. 2019 Apr 17:198-209.

23. Aso E, Fernández-Dueñas V, López-Cano M, Taura J, Watanabe M, Ferrer I, Luján R, Ciruela F. Adenosine A(2A)-Cannabinoid CB(1) Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Δ(9)-Tetrahydrocannabinol-Induced Cognitive Impairment. Mol Neurobiol. 2019 Aug 56:5382-5391.

24. Silva-Abreu M, Calpena AC, Andrés-Benito P, Aso E, Romero IA, Roig-Carles D, Gromnicova R, Espina M, Ferrer I, García ML, Male D. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. Int J Nanomedicine. 2018 Sep 20;13:5577-5590.

25. Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol. 2018 Nov 157:67-84.

26. Aso E, Andrés-Benito P, Ferrer I. Genetic deletion of CB(1) cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. Biochem

Comparteix-ho:
Facebook
Twitter
LinkedIn
Email

Portals i intranets